R&D (Research and development)

Products/Pipeline

Drug Development Pipeline (As of November 2024)

Products

Approved Drug

ETUARY^®(艾思瑞^® in Chinese): Indication : Idiopathic Pulmonary Fibrosis （Obtained Manufacturing and Distribution Permission in December, 2013）
（Start selling as the Class 1.1 in February, 2014）

Clinical Development Stage

ETUARY^®(艾思瑞^® in Chinese): Radiation-induced Pneumonitis：Launched pre-Phase III clinical trial pilot study

F351: Indication: Liver Fibrosis- Top-line data from Phase Ⅲ clinical trials
Indication: Chronic Kidney Failure (CKD)- Preclinical stage

IND(Investigational new drug application) Stage

ETUARY^®(艾思瑞^® in Chinese): Indication: Diabetic Nephropathy(DN)-Completed PhaseⅠclinical trials
Indication: Connective Tissue Disease Associated Interstitial Lung Disease (CTD-ILD) -PhaseⅢ clinical trials

F573: Indication: Acute liver failure/ Acute-on-chronic liver failure (ACLF) -PhaseⅡclinical trials